Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, a precision medicine company focused on transplant patient solutions, announced its participation in the Goldman Sachs Global Healthcare Conference. The management will engage in a fireside chat on June 9, 2020, at 11:20 AM EDT. Interested stakeholders can access a live webcast through the company’s website. CareDx specializes in products and services that enhance the pre- and post-transplant experience, providing genomics-based information vital for transplant patients.
CareDx, Inc. (Nasdaq: CDNA) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 11:00 AM EDT. The company, recognized for its precision medicine solutions for transplant patients, will provide a live webcast of its presentation available on its investor website. CareDx focuses on developing and commercializing high-value healthcare solutions and offers a range of products and services to support transplant patients and their caregivers.
CareDx, Inc. (Nasdaq: CDNA) has announced receiving CE mark approval for its AlloSeq Tx 17 technology, enhancing its availability for transplant patients, laboratories, and clinicians globally. This state-of-the-art solution offers superior donor organ matching and eliminates PCR disadvantages, improving workflow in Histocompatibility & Immunogenetics labs. Launched in September 2019, AlloSeq Tx 17 utilizes next-generation Hybrid Capture technology for HLA testing. CareDx aims to enhance patient care with genomics-based information, reinforcing its leadership in precision medicine for transplant solutions.
CareDx, Inc. (Nasdaq: CDNA) has formed a strategic alliance with Weill Cornell Medicine to become the exclusive partner for the development and commercialization of UroMap, a urine-based gene-expression test aimed at detecting acute cellular rejection in kidney transplant recipients. UroMap demonstrates high accuracy in identifying rejection episodes and may predict future occurrences. This collaboration enhances CareDx's portfolio of kidney transplant solutions, including AlloSure® and KidneyCare™. The exclusive rights for UroMap were secured through a license agreement with Cornell University.
Summary not available.
Summary not available.